Tagatose: from a sweetener to a new diabetic medication?

Bibliography

• Levin GV, Zehner LR, Saunders JP. Sugar substitutes: their energy values, bulk characteristics and potential health benefits. Am J Nutr 1995;62(Suppl):1161S-8S
   PubMedGoogle Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32(1):193-203
   PubMed Web of Science ®Google Scholar
• Gardner DG, Shoback D. Greenspan's basic and clinical endocrinology. 8th edition. McGraw Hill Medical, New York; 2007. p. 697-701
   Google Scholar
• Van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag 2008;4(6):1189-95
   PubMedGoogle Scholar
• Bastarrachea RM, Montero JC, Saavedra-Gajardo I, Molecular targets for new drug discovery to treat type 2 diabetes and obesity. Rev Med Chil 2008;136(1):107-17
   PubMed Web of Science ®Google Scholar
• Normen L, Laerke HN, Jensen BB, Small-bowel absorption of D-tagatose and related effects on carbohydrate digestibility: an ileostomy study. Am J Clin Nutr 2003;73(1):105-10
   Google Scholar
• Livesey G, Brown JC. D-Tagatose is a bulk sweetener with zero energy determined in rats. J Nutr 1996;126(6):1601-9
   Google Scholar
• Levin GV. Tagatose, the new GRAS sweetener and health product. J Med Food 2002;5(1):23-36
   PubMedGoogle Scholar
• Donner TW, Wilbur JF, Ostrowski D. D-Tagatose, a novel hexose: acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes. Diabetes Obes Metab 1999;1(5):285-91
   PubMed Web of Science ®Google Scholar
• Ibrahim OO, Spradlin JE. Process for manufacturing D-tagatose. 2000. Available from: http://www.uspto.gov/patft/ index.html
   Google Scholar
• Kim P. Current studies on biological tagatose production using L-arabinose isomerase: a review and future prospective. Appl Microbiol Biotechnol 2004;65(3):243-9
   PubMedGoogle Scholar
• Buemann B, Toubro S, Astrup A. Human gastrointestinal tolerance to D-tagatose. Regul Toxicol Pharmacol 1999;29:S71-7
   PubMed Web of Science ®Google Scholar
• Buemann B, Toubro S, Raben A, Astrup A. Human tolerance to a single high dose D-tagatose. Regul Toxicol Pharmacol 1999;29:S66-70
   Google Scholar
• Buemann B, Toubro S, Raben A, The acute effect of D-tagatose on food intake in human subjects. Br J Nutr 2000;84(2):227-31
   PubMed Web of Science ®Google Scholar
• Laerke HN, Jensen BB. D-Tagatose has a low small intestine digestibility but high large intestinal fermentability in pigs. J Nutr 1999;129(5):1002-9
   PubMed Web of Science ®Google Scholar
• Bertelsen H, Andersen H, Tvede M. Fermentation of D-tagatose by human intestinal bacteria and dairy lactic acid bacteria. Microb Ecol Health Dis 2001;13:87-95
   Google Scholar
• Pyun YR, Kim BC, Lee HS, Thermostable L-Arabinose Isomerase and process for preparing D-tagatose. 2005. Available from: http://www.uspto.gov/patft/index.html. [cited]
   Google Scholar
• Hansen OC, Jorgensen F, Stougaard P, Thermostable isomerase and use thereof, in particular for producing tagatose. 2006. Available from: http://www.uspto.gov/patft/index.html. [cited]
   Google Scholar
• Johansan HN, Jensen BB. Recovery of energy as SCFA after microbial fermentation of D-tagatose. Int J Obes 1997;21(Suppl 2):S50
   Google Scholar
• Bar A. D-tagatose, dossier prepared and submitted by Bioresco on behalf of Arla Food Ingredients amba, Viby Denmark for evaluation pursuant to EU Novel Foods Regulation (EC) 258/97 by the UK Advisory Committee on Novel Foods and Processes. 2004. Available from: http://www.foodstandards.gov.uk/multimedia/pdfs/tagatoseapplicationdossier.pdf. [cited]
   Google Scholar
• FSANZ. Final Assessment Report, Application A472, D-tagatose as a novel food. 2004. Available from: http://www.foodstandards.gov.au/_srcfiles/A472_D_tagatose_FAR.pdf. [cited]
   Google Scholar
• Buemenn B, Toubro S, Astrup A. D-Tagatose, a stereoisomer of D-Fructose, increases hydrogen production in humans without affecting 24-hour expenditure or respiratory exchange ratio. J Nutr 1998;128:1481-6
   PubMed Web of Science ®Google Scholar
• Buemann B, Toubro S, Holst JJ, D-Tagatose, a stereoisomer of D-fructose increases blood uric acid concentration. Metabolism 2000;49(8):969-76
   PubMed Web of Science ®Google Scholar
• Lu Y, Levin GV, Donner TW. Tagatose, a new antidiabetic and obesity control drug. Diabetes Obes Metab 2008;10:109-34
   PubMed Web of Science ®Google Scholar
• Seri K, Sanai K, Negeshi S, Akino T. Prophylactic and remedial preparation for disease attendant on hyperglycemia and wholesome food. 1993: US
   Google Scholar
• Madenokoji N, Iino H, Shimizu T, Blunting effect of D-tagatose on blood glucose when administered orally with glucose in volunteer donors of boundary glycemic control. J Jpn Soc Clin Nutr 2003;25:21-8
   Google Scholar
• Sigrist-Nelson K, Hopfer U. A distinct D-fructose transport system in isolated brush border membrane. Biochem Biophys Acta 1974;367:247-54
   PubMed Web of Science ®Google Scholar
• Van den berghe G, Hue L, Hers HG. Inhibition in vivo of the hyperglycemic action of glucagon: study of the pathogeny of hereditary fructose intolerance. Pediatr Res 1974;8:910
   Web of Science ®Google Scholar
• Bollen M, de Ruysscher D, Stalmans W. On the mechanism of hepatic glycogenolysis induced by anoxia or cyanide. Biochem Biophys Res Commun 1983;15:1033-9
   Web of Science ®Google Scholar
• Van Schaftingen E, Vandercammen A. Stimulation of glucose phosphorylation by fructose in isolated rat hepatocytes. Eur J Biochem 1989;179:173-7
   PubMedGoogle Scholar
• Kruger CL, Whittaker MH, Frankos VH, Trimmer GW. 90-day oral toxicity study of D-tagatose in rats. Regul Toxicol Pharmacol 1999;29:S1-10
   PubMed Web of Science ®Google Scholar
• Hertel S Wv. Saccharase/isomaltase und glucoamylase/maltase aus schweinendunndarmmukosa mit substraten und inhibition. PhD thesis, University of Hanover, Germany 1997
   Google Scholar
• Buemann B, Gesmar H, Astrup A, Quistorff B. Effects of Oral D-Tagatose, a stereoisomer of D-Fructose on liver metabolism in man as examined by P-magnetic resonance spectroscopy. Metabolism 2000;49:1225-339
   Google Scholar
• Agius L. Control of glucokinase translocation in rat hepatocytes by sorbitol and the cytosolic redox state. Biochem J 1994;198:237-43
   Google Scholar
• Agius L. The physiological role of glucokinase binding and translocation in hepatocytes. Adv Enzyme Regul 1998;38:303-31
   PubMedGoogle Scholar
• Niculescu L, Veiga-da-Cunha M, Van Schaftingen E. Investigation on the mechanism by which fructose, hexitols, and other compounds regulate the translocation of glucokinase in rat hepatocytes. Biochem J 1997;321:239-46
   PubMed Web of Science ®Google Scholar
• Agius L, Peak M, Newgard CB, Evidence for a role of glucose-induced translocation of glucokinase in the control of hepatic glycogen synthesis. J Biol Chem 1996;271:30479-86
   PubMed Web of Science ®Google Scholar
• Gergely P, Toth B, Farkas I, Bot G. Effect of fructose 1-phosphate on the activation of liver glycogen synthase. Biochem J 1985;232:133-7
   Google Scholar
• Ercan-Fang N, Gannon MC, Rath VL, Integrated effects of multiple modulators on human liver glycogen phosphorylase alpha. Am J Physiol Endocrinol Metab 2002;283(1):E29-37
   PubMed Web of Science ®Google Scholar
• Donner T. The metabolic effects of dietary supplementation with D-tagatose in patients with type 2 diabetes. Diabetes 2006;55(Suppl 1):A110; 461P
   PubMedGoogle Scholar
• Donner TW, Wilbur JF, Ostrowski D. D-tagatose: a novel therapeutic adjunct for non-insulin dependent diabetes [abstract]. Diabetes;1996;45(Suppl 2): 125A
   Google Scholar
• Masoro E. Aging and proliferative homeostasis: modulation by food restriction in rodents. Lab Anim Sci 1992;42:132-7
   PubMedGoogle Scholar
• Bar A, Lina BA, de Groot DM, Effects of D-tagatose on liver weight and glycogen content of rats. Regul Toxicol Pharmacol 1999;29:S11-28
   PubMed Web of Science ®Google Scholar
• Bar A. Characteristics and significance of D-tagatose-induced liver enlargement in rats: an interpretive review. Regul Toxicol Pharmacol 1999;29:S83-93
   PubMed Web of Science ®Google Scholar
• Boesch C, Ith M, Jung B, Effect of oral D-tagatose on liver volume and hepatic glycogen accumulation in healthy male volunteers. Regul Toxicol Pharmacol 2001;33:257-67
   PubMed Web of Science ®Google Scholar
• Saunders JP, Donner TW, Sadler JH, Effects of acute and repeated oral doses of D-tagatose on plasma uric acid in normal and diabetic humans. Regul Toxicol Pharmacol 1999;29:S57-65
   PubMed Web of Science ®Google Scholar
• AACE. The State of Diabetes in America: Executive Summary. 2003-2004 [Available from: http://www.aace.com/public/awareness/stateofdiabetes/DiabetesAmericaReport.pdf] page 1-9
   Google Scholar
• Finfer S, Chittock DR, Su SY, ; Investigators, TNS. Intensive versus conventional glucose control in critically ill patients. NEJM 2009;360:1283-97
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, Effects of intensive glucose lowering in type 2 diabetes. NEJM 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C. Targeting prandial hyperglycemia: how important is it and how best to do this? Curr Diabetes Rep 2008;8:368-74
   PubMed Web of Science ®Google Scholar
• Ceriello A. The emerging role of post-prandial hyperglycemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998;15:188-93
   PubMed Web of Science ®Google Scholar
• Hanefield M, Fischer S, Julius U, Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Interventional Study, 11-year follow-up. Diabetologia 1996;39:1577-83
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type two diabetes mellitus. Circulation 2004;110:214-19
   Google Scholar
• Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009;8:23
   Google Scholar
• Hanefeld M, Chiasson JL, Koehler C, Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073-8
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003;290:486-94
   PubMed Web of Science ®Google Scholar